Date: 2018-10-16
Type of
information: Initiation of development program
phase: preclinical
Announcement: initiation of development program
Company: BioInvent (Sweden)
Product: BI-1808
Action
mechanism:
- monoclonal antibody - immune checkpoint inhibitor
Disease: solid tumors
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On October 16, 2018, BioInvent announced its intention to initiate three new clinical programs in solid cancer. In addition to the previously disclosed programs (BI-1206 + rituximab – projected topline results H1 2020; and the Transgene and Pfizer collaborations), and subject to successful preclinical results and sufficient financial resources, BioInvent intends to advance the BI-1808 (anti-“EmergingTNFRS” antibody) +/- anti-PD1 antibody program in solid cancer (projected start phase l in H1 2020).
Is
general: Yes
